ArticleScience advances2026
Membrane-associated Rhes-Slc4a7 complex orchestrates tunneling nanotube formation and mutant Huntingtin spread.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protein farnesylation: from molecular mechanisms to therapeutic targeting in cancer, aging, and beyond.Frontiers in pharmacology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
Tunneling nanotubes (TNTs) are membranous structures that mediate intercellular transfer of proteins, including the pathogenic mutant Huntingtin (mHTT) protein in Huntington disease (HD). We previously identified the ras homolog enriched in the striatum (Rhes) as a key regulator of TNT formation and mHTT transmission; however, the molecular components underlying this process remained unknown. Here, using unbiased liquid chromatography-tandem mass spectrometry analysis of membrane-associated Rhes complexes, we identify Slc4a7 (solute carrier family 4 member 7), an intracellular pH sensor, as a top membrane-binding partner of Rhes. Functional studies revealed that small interfering RNA-mediated depletion or pharmacological inhibition of Slc4a7 substantially reduced Rhes-induced TNT formation and suppressed mHTT intercellular transfer. Mechanistically, Rhes directly interacts with Slc4a7 through both its amino- and carboxyl-terminal domains and modulates intracellular pH to facilitate TNT formation. This interaction does not depend on the transporter activity of Slc4a7. However, inhibition of Rhes farnesylation-a lipid modification that anchors Rhes to the membrane-disrupts its binding to Slc4a7 and abolishes TNT formation. Slc4a7 knock-out mice showed markedly reduced cell-to-cell transmission of mHTT in the striatum in vivo. Together, these findings uncover a previously unrecognized Rhes-Slc4a7 signaling axis critical for TNT-mediated mHTT transmission and highlight Slc4a7 as a potential therapeutic target to limit disease spread in HD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.